Kenvue Inc. News
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
see moreKenvue Inc. Market News
8d
Kenvue's Stock Rises as Analysts Show Confidence Ahead of Key Earnings Report
- Kenvue's stock performance amidst recent developments in the consumer health sector.
15d
Kenvue's Financial Growth Faces Investor Scrutiny Following Major Stake Sale
Kenvue's stock performance amid recent consumer health sector developments.
22d
Kenvue's Strategic Moves and Financial Performance Amidst Industry Shifts
Kenvue's recent financial results and strategic initiatives in the consumer health sector.
28d
Kenvue's Stock Performance Amidst Recent Developments in the Consumer Health Sector
Kenvue's stock performance amid recent consumer health sector developments.
26 May at 14:10
Kenvue Q1 Beat Spurs Momentum Ahead of KC Deal Now
Kenvue reported a stronger-than-expected Q1 with improved margins and modest organic growth, prompting analyst upgrades and renewed investor interest as the Kimberly‑Clark acquisition advances. Dividend actions and restructuring reinforce near-term valuation drivers for the S&P 500 consumer-health name.
19 May at 14:10
Kenvue Q1 Beat: Dividend Kept, Deal Risk Stays Now
Kenvue reported a Q1 earnings and revenue beat, driven by Skin Health & Beauty growth and margin expansion. Management withheld guidance due to the pending Kimberly‑Clark acquisition. The company maintained its quarterly dividend while insiders trimmed positions and Fidelity disclosed a meaningful stake — factors that shape near‑term investor decisions.
12 May at 14:10
Kenvue Q1 Beat Fuels Kimberly-Clark Deal Case Now!
Kenvue’s Q1 2026 results topped estimates—adjusted EPS $0.32 and $3.91B in sales—strengthening confidence in the pending Kimberly‑Clark acquisition. This article explains the financials, deal implications, and sector-level regulatory and litigation risks that investors should monitor.